Short Interest in Ampio Pharmaceuticals Inc (AMPE) Rises By 1.1%
Ampio Pharmaceuticals Inc (NYSEAMERICAN:AMPE) saw a large growth in short interest in the month of September. As of September 14th, there was short interest totalling 14,359,784 shares, a growth of 1.1% from the August 31st total of 14,197,885 shares. Based on an average daily trading volume, of 1,343,049 shares, the days-to-cover ratio is currently 10.7 days. Currently, 14.6% of the company’s shares are sold short.
A number of institutional investors have recently added to or reduced their stakes in AMPE. Rhumbline Advisers acquired a new position in Ampio Pharmaceuticals during the 2nd quarter worth approximately $154,000. Valeo Financial Advisors LLC acquired a new position in shares of Ampio Pharmaceuticals in the 2nd quarter valued at approximately $155,000. A.R.T. Advisors LLC acquired a new position in shares of Ampio Pharmaceuticals in the 1st quarter valued at approximately $258,000. Element Capital Management LLC acquired a new position in shares of Ampio Pharmaceuticals in the 1st quarter valued at approximately $290,000. Finally, Schwab Charles Investment Management Inc. acquired a new position in shares of Ampio Pharmaceuticals in the 2nd quarter valued at approximately $326,000.
NYSEAMERICAN AMPE opened at $0.53 on Thursday. Ampio Pharmaceuticals has a 1-year low of $0.35 and a 1-year high of $4.95.
About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States. The company is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process; and decreasing vascular permeability.
Further Reading: Diversification
Receive News & Ratings for Ampio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.